We write to comment on the recent paper by Rowe et al.
and our comments here, require that there be a fundamental re-consideration of these outcome measures before they are implemented in a future full-scale clinical trial.
Participants were randomized to one of three arms: (i) peripheral prism glasses, (ii) visual search training, or (iii) standard care. Peripheral prism glasses are designed as a mobility aid to assist with detection of blind side obstacles. 3 When the prisms are worn, they provide expansion of the field of view measurable with standard perimetry, 3-5 which has been reported by patients to be helpful for obstacle avoidance when walking. 3, 4, 6, 7 When not worn, the prisms are not expected to provide any help or effect. Visual search training is expected to increase visual exploration (scanning) toward the blind hemifield, [8] [9] [10] which may in turn improve detection of objects on the blind side. 8, 11 Outcome measures should be selected to be relevant to the ex- 12 and responses to pedestrian hazards in a driving simulator. 13 All these measures were found to be responsive to the intervention.
In the Rowe et al. pilot study, participants were recruited between 2 and 26 weeks post-stroke. Prior research suggests that there may be spontaneous recovery of the visual field up to 3 months (12 weeks) or even 6 months (24 weeks) following the stroke. 14 Therefore, it is quite possible that some participants might have experienced some recovery of the visual field, and it was appropriate to check visual fields at the end of the trial as a control, but not as a primary outcome. In the discussion of the pilot results paper, 1 the authors report "minimal non-significant increase in visual field across all three arms of 5, 8, and 3.5%" and then go on to state "the insignificant change in visual field was expected given the deliberate recruitment of stable hemianopes to the trial. Other trials recruiting stable hemianopes also report no significant change to extent of visual field loss". Yet, the visual field measure was described as the "primary efficacy outcome" (results paper, 1 section 2.10), which implies that the interventions were expected to result in some recovery of the visual field (ie an increase in area from baseline). If the authors expected no significant change in the visual field, then it is hard to understand why a change in visual field area was included as the primary measure of efficacy.
There are many reasons to suggest that visual field area should not ). These statements may be true for some of the questionnaires in some instances, but no supporting evidence was cited. More importantly, the authors did not specifically address whether there was any evidence that the questionnaires were sensitive (relevant) to the expected effects of the interventions used in their pilot study. Indeed, one questions whether the VFQ-25 would be a good outcome measure because it includes very few questions that are specific to the expected effects of visual search training or the use of peripheral prism glasses. Similarly, the Rivermead Mobility Index has many items which relate to physical limitations on mobility (eg moving from lying to sitting; running 10 m in 4 seconds), which are unlikely to be responsive to either a visual or an oculomotor rehabilitation strategy, making it not valid for use in this context.
Performance on the Radner reading test was also included as a secondary outcome measure. 1,2 However, it had been previously reported that reading speed was unaffected by compensatory scanning training. [8] [9] [10] In a cross-over study in which specific oculomotor training to rehabilitate reading was provided, in addition to compensatory scanning training, it was found that the training was specific to the intended modality, and did not transfer to the other task. 16 Peripheral prism glasses were also never intended to help with reading, and patients are usually told not to wear them for prolonged reading. 3, 4, 6 Therefore, the reading measure was irrelevant to the expected effects of either therapy, and no rationale was given for why it was used as an outcome measure. Systematic reviews 15, 17 have highlighted the need for randomized clinical trials of interventions for patients with homonymous visual field loss, and we would fully support this contention. The pilot trial by
Rowe and colleagues was undoubtedly well intentioned in this respect.
However, the primary outcome measure (change in visual field area) could never have provided any useful information about the efficacy of the two interventions and, therefore, is also inappropriate as the basis for a sample size calculation for a future clinical trial. 
